on SWK Holdings Corp.
SWK Holdings Updates Portfolio and Announces Q3 Earnings Date
SWK Holdings Corporation, specializing in life science finance, has announced the timing for its third-quarter earnings release and conference call. The financials will be published after market close on November 14, 2024, followed by a conference call on November 15, 2024.
In portfolio updates, SWK expanded Eton Pharmaceuticals' credit facility to $30 million, supporting Eton’s acquisition of Increlex. Epica International repaid an $8.3 million loan, with SWK retaining equity interest.
Notable performance updates include AOTI, Inc. reporting a 26.4% revenue increase and Biotricity, Inc. projecting profitability by the fiscal fourth quarter. Meanwhile, Elutia Inc. reported significant sales growth, and Journey Medical Corporation saw a 14% revenue increase.
Eton Pharmaceuticals achieved 40% year-over-year revenue growth. MolecuLight closed a $11.7 million financing round, and Shield Therapeutics reported a 320% revenue increase.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SWK Holdings Corp. news